Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) reported April 14, 2026 HT-VA preclinical data showing parenteral GDNF reprograms liver fat metabolism. Key findings include a statistically significant reduction in Srebf1 and an increase in Pparα, plus gene-expression improvements vs semaglutide.
The company plans additional preclinical validation, evaluation of clinical development paths for MAFLD and obesity, and potential partnerships to accelerate development.
Positive
- Statistically significant Srebf1 reduction in HT-VA preclinical study
- Statistically significant increase in Pparα expression in HT-VA study
- GDNF outperformed semaglutide on key liver gene-expression markers
Negative
- Findings are limited to a preclinical diet-induced MAFLD model; human efficacy unproven
- No quantitative clinical efficacy, safety, or timelines disclosed for patient studies
News Market Reaction – HOTH
On the day this news was published, HOTH gained 26.18%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -31.5% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $13.77M at that time. Trading volume was exceptionally heavy at 12.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
HOTH was down 0.74% pre-release while peers showed mixed moves: CRIS up 23.98%, PASG up 9.63%, QTTB up 7.55%, and LSTA and ELEV down modestly. Momentum scanner shows 4 peer names moving up, but this contrasts with HOTH’s slight decline, pointing to stock-specific dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Financing closed | Negative | +3.0% | Closing of $2.0M registered direct offering with concurrent warrants. |
| Apr 01 | Financing announced | Negative | -34.9% | Announcement of $2.0M registered direct share and warrant offering. |
| Apr 01 | Clinical milestone | Positive | -34.9% | HT-001 Phase 2 interim data meeting primary endpoint and enabling expansion. |
| Mar 31 | Patent issued | Positive | +9.1% | Grant of Chinese patent for splice-switching mast cell apoptosis platform. |
| Mar 26 | Platform deployment | Positive | -6.7% | Launch of OpenClaw™ AI platform to accelerate discovery across pipeline. |
News reactions have been inconsistent: positive clinical and platform updates have sometimes coincided with sharp declines, while dilutive financings have seen both selloffs and modest rebounds.
Over recent weeks, Hoth has mixed clinical, strategic, and financing signals. On March 26, 2026, AI platform OpenClaw™ deployment drew a -6.65% move. A Chinese patent grant on March 31 coincided with a 9.12% gain. On April 1, strong HT-001 Phase 2 interim data and a registered direct offering each saw -34.86% reactions. The offering’s closing on April 2 then produced a modest 3.04% rise. Today’s HT-VA metabolic data adds another clinically focused milestone to that sequence.
Regulatory & Risk Context
An effective Form S-3 shelf filed on November 14, 2025 allows Hoth to offer up to $50 million of various securities, and it has already been tapped via at least one 424B5 prospectus supplement for a registered direct offering. This structure provides flexibility to raise additional capital as needed.
Market Pulse Summary
The stock surged +26.2% in the session following this news. A strong positive reaction aligns with the significance of gene-level effects in MAFLD and obesity, but past trading shows mixed responses to good news. Prior clinical and platform updates sometimes coincided with declines of 6–35%, and recent financings used an existing $50 million shelf. Investors would have weighed clinical promise against capital needs and historical volatility.
Key Terms
gdnf medical
srebf1 medical
pparα medical
semaglutide medical
glp-1 agonists medical
mafld medical
nash medical
lipogenesis medical
AI-generated analysis. Not financial advice.
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity
The data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.
- Statistically significant reduction in Srebf1, a key gene driving fat production in the liver
- Increased expression of Pparα, a central regulator of fat metabolism and fat burning
- GDNF outperformed semaglutide in key gene expression markers tied to liver fat regulation
- Demonstrated broad metabolic impact at the genetic level, not just weight reduction
Unlike existing therapies that primarily focus on weight loss, GDNF directly targets the biological mechanisms responsible for fat accumulation in the liver.
- Srebf1 reduction → less fat being created
- Pparα activation → more fat being burned
- Net effect → reprogramming of liver metabolism
This dual mechanism suggests GDNF may offer a disease-modifying approach for MAFLD, obesity, and related metabolic disorders.
"HT-VA represents a major milestone for Hoth as we expand into high-value metabolic indications," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.
"These results demonstrate that GDNF is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists."
SCIENTIFIC SUMMARY (HT-VA STUDY)
The HT-VA study evaluated the effects of parenteral GDNF in a diet-induced obesity and MAFLD model.
Key observations include:
- Western diet significantly increased liver fat accumulation and metabolic dysfunction
- GDNF treatment significantly improved liver gene expression linked to fat metabolism
- Reduced lipogenesis signaling (Srebf1) and enhanced metabolic regulation pathways (Pparα)
- Gene expression changes support improved hepatic lipid handling and metabolic efficiency
STRATEGIC IMPLICATIONS
- Entry into MAFLD/NASH and obesity markets
- Differentiation vs. GLP-1 therapies through gene-level mechanism
- Potential for first-in-class metabolic reprogramming therapy
- Expansion beyond Hoth's core dermatology and oncology pipeline
NEXT STEPS
Hoth plans to:
- Advance HT-VA findings into additional preclinical validation studies
- Evaluate clinical development pathways for metabolic and liver diseases
- Explore strategic partnerships and collaborations to accelerate development
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide-302741263.html
SOURCE Hoth Therapeutics, Inc.